Observational pilot study of patients with carpal tunnel syndrome treated with Nucleo CMP Forte™.
Pain Manag
; 9(2): 123-129, 2019 Mar 01.
Article
em En
| MEDLINE
| ID: mdl-30451573
ABSTRACT
AIM:
Carpal tunnel syndrome (CTS) is a very common entrapment neuropathy characterized by pain and paresthesia in the territory of the median nerve. Although this syndrome has a considerable impact on the patient's quality of life, its medical treatment is far from optimal. MATERIAL &METHODS:
We performed an observational study to evaluate Nucleo CMP ForteTM in patients with electromyography-confirmed, mild-moderate CTS. Pain was assessed using a visual analog scale, electromyogram and the SF-36.RESULTS:
Pain decreased significantly after 6 months. Quality of life improved significantly in the pain dimensions. No significant differences were observed in electromyographic findings. No adverse events were reported.CONCLUSIONS:
Nucleotides could prove useful for the nonsurgical treatment of CTS. Further studies are necessary to confirm this.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Dor
/
Uridina Monofosfato
/
Síndrome do Túnel Carpal
/
Monofosfato de Citidina
/
Analgésicos
Tipo de estudo:
Etiology_studies
/
Observational_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article